关于调强放疗对前列腺癌患者临床价值的实验研究  

Empirical study for clinical value of intensity-modulated radiotherapy for prostate cancer

作　　者：李小武[1] 范立[1] 韩晓栋[1] 

机构地区：[1]山西省肿瘤医院,山西太原030013

出　　处：《临床医药实践》2012年第2期83-85,共3页Proceeding of Clinical Medicine

摘　　要：目的:探讨调强放疗技术(IMRT)在前列腺癌应用中的临床价值。方法:选取就诊的34例前列腺癌患者进行调强放射加内分泌治疗,观察急、慢性放射反应发生率、严重程度及3,5年生存率。结果:急、慢性期直肠、膀胱放射反应发生率较低,所有患者3,5年总生存率为85.29%和79.41%,无生化失败生存率为70.59%和61.76%。结论:前列腺癌患者接受IMRT放疗加内分泌治疗后,患者具有较高的生存率,且放疗毒副作用可接受。Objective：To observe the clinic value about intensity-modulated radiotherapy （IMRT） for prostate cancer. Methods ：Thirty-four prostate cancer patients were cured by intensity-modulated radiotherapy and endocrine therapy. To observer the acute and chronic radioreaction and survival rates of 3 - , 5 - years. Results ： The frequency of acute and chronic rectal and bladder toxicity were low . The 3 - and 5 - year overall survival rate was 8 5 . 2 9 % and 79.41 ~. The 3-and 5-year disease-free survival rate were 70.59 % and 61.76 %. Conclution ：Prostate cancer patients after cured by IMRT radiotherapy had high survival rate and the radioreaction could be tolerated.

关 键 词：调强放疗 前列腺癌 急性放射反应 慢性放射反应 

分 类 号：R737.25[医药卫生—肿瘤]